Skip to main content
OpenTrials
Completed

NCT Number: NCT06605300

The Effects of Oxytocin and Vasopressin on Delta-beta Cross-frequency Coupling

The main aim of the study is to investigate whether intranasal oxytocin and vasopressin have effects on delta-beta cross-frequency coupling under resting-state and task conditions.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy Diabetes Insipidus Endocrine System Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Kidney Diseases Male Urogenital Diseases Pituitary Diseases Urogenital Diseases Urologic Diseases

Age range

18 year–30 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Electronic Science and Technology of China, Chengdu, China

Loading trial locations.

About this study

A double-blinded, placebo-controlled, between-subject design is employed in this study. In a randomized order, a total of 120 healthy males and females are instructed to self-administer intranasal spray of oxytocin, vasopressin, or placebo. (1) 15-minute resting-state EEG data are collected 35 minutes after treatment. (2) Participants complete tasks including Stroop, GO/NOGO, and anxiety induction with behavioral (response time, accuracy, or rating) and EEG data being collected. Personality traits of subjects are assessed using validated Chinese version questionnaires including the Beck Depression Inventory (BDI-II), State-Trait Anxiety Inventory (STAI), Autism Spectrum Quotient (ASQ), and Adult ADHD Self-Report Scale (ASRS-v1.1). Participants are asked to complete Positive and Negative Affect Schedule (PANAS) when they just arrive, before resting state and after the tasks. Three blood samples (5 ml) are collected into 6 ml ETDA tubes when participants just arrive, before resting state recording and after all of the tasks.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy subjects without past or current psychiatric or neurological disorders.

Exclusion criteria

  • History of head injury.
  • Pregnant,menstruating,taking oral contraceptives.
  • Medical or psychiatric illness.

Treatment and study plan

Intranasal Oxytocin (IN-OXT)

Drug

Subject assigned to receive intranasal administration of oxytocin (24 IU).

Intranasal Vasopressin (AVP)

Drug

Subjects assigned to receive intranasal administration of vasopressin (20 IU).

Intranasal placebo

Drug

Subjects assigned to receive intranasal administration of placebo.

Primary outcomes

  1. Resting-state EEG

    Time frame: 35-50 minutes after treatment administration.

    Participants are asked to sit comfortably and look at a white cross fixation against a black background on the computer monitor for 15 minutes with delta-beta cross-frequency coupling as a main index.

  2. Behavioral indices in the tasks

    Time frame: 50-90 minutes after treatment administration.

    Reaction time and accuracy are recorded in the emotional Stroop and Go/Nogo tasks. For the anxiety induction task, participants are instructed to rate their anxiety levels using a 9-point Likert scale within 4 seconds (1 = not at all, 9 = very anxious).

  3. Task-based EEG

    Time frame: 50-90 minutes after treatment administration.

    EEG data are recorded in the emotional Stroop, Go/Nogo, and anxiety induction tasks. Delta-beta cross-frequency coupling will be calculated to do statistical analyses.

Secondary outcomes

  1. SCR in anxiety induction

    Time frame: 70-90 minutes after treatment administration.

    Skin Conductance Response (SCR) data are recorded in the anxiety induction task under safe and anxious conditions.

Sponsors and collaborators

Lead sponsor

University of Electronic Science and Technology of China

Other

Registry information

Official study title

The Modulatory Effects of Oxytocin and Vasopressin on Delta-beta Cross-frequency Coupling

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Sep 20, 2024
Registry last updated
Oct 3, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.